While these findings highlight MMR’s therapeutic promise, it remains unclear whether MMR-driven immunovirotherapy can synergize with ICB to induce durable tumor control and extend survival in preclinical HCC models. This evidence concerns the gene MRC1 and hepatocellular carcinoma.